Structure Therapeutics’ Oral GLP-1 Achieves Comparable Weight Loss to Lilly’s Candidate

1. Weight Loss Results: Structure Therapeutics' oral GLP-1 receptor agonist, GSBR-1290, showed a placebo-adjusted mean weight loss of up to 6.9% in a 12-week pharmacokinetics study, comparable to Lilly's oral GLP-1 candidate.
2. Phase IIa Studies: The company reported positive results from two mid-stage studies, with the daily pill in a capsule formulation leading to 6.2% placebo-adjusted weight loss in a 12-week Phase 2a study.
3. Stock Surge: Shares of Structure Therapeutics surged more than 54% following the release of the data, closing at $52.74 on June 3, 2024.
4. Competitive Obesity Market: Structure Therapeutics aims to position GSBR-1290 in the highly competitive obesity market, where it faces competition from more advanced oral GLP-1 candidates.
5. CEO Statement: Raymond Stevens, CEO of Structure Therapeutics, highlighted the significance of the results, which demonstrate the potential of GSBR-1290 in the obesity treatment landscape.